Corline Biomedical AB (IZ7)

Overview

Corline Biomedical AB is an innovator in the field of biomedical sciences, focusing on the development, manufacturing, and marketing of heparin-based solutions. These solutions are designed to improve outcomes in kidney transplantation, cell therapies, and regenerative medicine. The company leverages its proprietary Corline Heparin Conjugate (CHC) technology as a cornerstone in its product lineup, offering a pharmaceutical compound that stands alone in its revolutionary approach to treatment. Since its incorporation in 1991, Corline Biomedical AB has established its headquarters in Uppsala, Sweden, where it continues to pioneer advancements in medical applications of heparin.

Products and Services

• Renaparin:

  A heparin-based solution specifically designed for the treatment of end-stage renal failure. Renaparin represents a significant advancement in the management of patients undergoing kidney transplantation, aimed at improving the outcomes and longevity of the transplanted organs.

• Cytoparin:

  This cell therapy is targeted at treating patients with type 1 diabetes. Cytoparin utilizes the unique properties of heparin to support the survival and function of transplanted cells, offering new hope for individuals with this chronic condition.

• CHC (Corline Heparin Conjugate):

  At the heart of Corline Biomedical's product range is CHC, a versatile heparin conjugate used for the treatment of soft tissue injuries. Its application in regenerative medicine showcases the potential of heparin beyond its traditional use, providing a novel approach to healing and recovery.